Evaluation of gefitinib alone or combined with bevacizumab in patients with <i>EGFR</i> L858R-positive advanced non-squamous non-small cell lung cancer: an open-label, randomized, phase 2 trial (BEVA-FLFX-001) with exploratory analysis of plasma biomarkers.

Transl Lung Cancer Res · 2025 · PMC12605247 · PMID 41234598

Europe PMC DOI

hedged sentence

0.0700

closest p · 1.4× alpha

0.0700

boldest claim

The sentences

nearly significantP=0.07so close (0.05 < p ≤ 0.1)

As shown in Figure 3A , gefitinib-treated patients who tested positive for ctDNA (ctDNA+) at baseline exhibited a nearly significant reduction in PFS compared to those with a negative ctDNA status (ctDNA-) [mPFS: 7.6 vs. 15.9 months, HR (95% CI): 2.66 (0.91–7.79); P=0.07].

also in 3,279 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.

Evaluation of gefitinib alone or combined with bevacizumab in patients with &lt;i&gt;EGFR&lt;/i&gt; L858R-positive advanced non-squamous non-small cell lung cancer: an open-label, randomized, phase 2 trial (BEVA-FLFX-001) with exploratory analysis of plasma biomarkers.

The sentences

Evaluation of gefitinib alone or combined with bevacizumab in patients with <i>EGFR</i> L858R-positive advanced non-squamous non-small cell lung cancer: an open-label, randomized, phase 2 trial (BEVA-FLFX-001) with exploratory analysis of plasma biomarkers.